News Releases

Date	Title and Summary	View
May 29, 2018	Johnson & Johnson to Participate in the Goldman Sachs 39th Annual Global Healthcare Conference NEW BRUNSWICK, N.J. , May 29, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12 , at the Terranea Resort in Rancho Palos Verdes , California. Tom Cavanaugh, President, Oncology, Janssen
May 22, 2018	Johnson & Johnson to Participate in the Jefferies 2018 Global Healthcare Conference
May 18, 2018	ERLEADA™ Significantly Reduced Risk of Prostate Specific Antigen (PSA) Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
May 16, 2018	Janssen to Present New Data in Urothelial, Hematologic and Prostate Cancers at ASCO 2018, Including Best of ASCO Selections
May 14, 2018	DePuy Synthes Signs Definitive Agreement to Acquire Assets of Medical Enterprises Distribution LLC to Strengthen its Portfolio and Amplify the Surgeon's Ability Via Automation
May 07, 2018	Janssen Announces DARZALEX® (daratumumab) U.S. FDA Approval for Newly Diagnosed Patients with Multiple Myeloma who are Transplant Ineligible
May 05, 2018	New Phase 3 Data Show Esketamine Nasal Spray Demonstrated Rapid Improvements in Depressive Symptoms in Patients with Treatment-Resistant Depression - Study in adults with treatment-resistant depression marks the first time an antidepressant has achieved superiority in a clinical trial for major depressive disorder that included a newly initiated oral antidepressant in both the control and placebo groups - Study in elderly patients is the first large clinical trial in treatment-resistant depression in this population - Results demonstrate the potential of esketamine nasal spray to address a significant unmet need for the more than 30 percent of people suffering from major depressive disorder who do not respond to two or more currently available antidepressants(1)
May 03, 2018	Johnson & Johnson to Participate in the 2018 UBS Global Health Care Conference NEW BRUNSWICK, N.J. , May 3, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 2018 UBS Global Health Care Conference on Monday, May 21 st , at the Grand Hyatt , New York . Sandi Peterson, Executive Vice President, Group Worldwide Chairman will represent the Company in a
May 02, 2018	Johnson & Johnson to Host Consumer and Medical Devices Business Review NEW BRUNSWICK, N.J. , May 2, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a review of its Consumer and Medical Devices businesses for the investment community beginning with a continental breakfast and access to exhibits at 8:00 a.m. (Eastern Time) on Wednesday, May 16, 2018 at the
Apr 30, 2018	Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT® (macitentan) for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)